TY - JOUR
T1 - Acupoint transcutaneous electrical nerve stimulation in hospitalized COPD patients with severe dyspnoea
T2 - Study protocol for a randomized controlled trial
AU - Fernández-Jané, Carles
AU - Vilaró, Jordi
N1 - Publisher Copyright:
© 2019 The Author(s).
PY - 2019/12/11
Y1 - 2019/12/11
N2 - Background: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a major cause of hospital admissions and dyspnoea is its main symptom. Some studies have concluded that a new modality of acupuncture, called acupoint transcutaneous electrical nerve stimulation (acuTENS), could reduce dyspnoea in patients with COPD by increasing ß-endorphin levels. However, those trials have been conducted mainly on patients in stable condition. This study aims to determine whether the administration of acuTENS can reduce dyspnoea in patients hospitalized for AECOPD. Methods: A multicentre randomized control trial with blinding of participants and assessors will be conducted. A sample of 60 patients will be randomly assigned to receive 45 min of either real acuTENS or sham acuTENS treatment once a day for five consecutive days. The trial will be conducted at the “Hospital del Mar” in Barcelona (Spain) and the “Hospital Sant Joan de Déu de Manresa” in Manresa (Spain). The Borg scale at baseline and days 1 to 5 will be the primary outcome. Secondary outcomes will be the duration of the hospitalization, quantity of drugs administrated, expiratory peak flow adverse effects and mortality and readmissions at 3 months. Discussion: AcuTENS is a non-pharmacological, non-invasive and inexpensive intervention. This trial will help to elucidate the potential role of acuTENS in the treatment of AECOPD. Trial registration: ClinicalTrials.gov identifier: NCT02998957. Recruitment status: Recruiting. First posted: 21 December 2016. Last update posted: 2 October 2018. Trial registration dataset is available in Additional file 1. Protocol version 03. Issue date: 20 March 2018. Author: Carles Fernández.
AB - Background: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a major cause of hospital admissions and dyspnoea is its main symptom. Some studies have concluded that a new modality of acupuncture, called acupoint transcutaneous electrical nerve stimulation (acuTENS), could reduce dyspnoea in patients with COPD by increasing ß-endorphin levels. However, those trials have been conducted mainly on patients in stable condition. This study aims to determine whether the administration of acuTENS can reduce dyspnoea in patients hospitalized for AECOPD. Methods: A multicentre randomized control trial with blinding of participants and assessors will be conducted. A sample of 60 patients will be randomly assigned to receive 45 min of either real acuTENS or sham acuTENS treatment once a day for five consecutive days. The trial will be conducted at the “Hospital del Mar” in Barcelona (Spain) and the “Hospital Sant Joan de Déu de Manresa” in Manresa (Spain). The Borg scale at baseline and days 1 to 5 will be the primary outcome. Secondary outcomes will be the duration of the hospitalization, quantity of drugs administrated, expiratory peak flow adverse effects and mortality and readmissions at 3 months. Discussion: AcuTENS is a non-pharmacological, non-invasive and inexpensive intervention. This trial will help to elucidate the potential role of acuTENS in the treatment of AECOPD. Trial registration: ClinicalTrials.gov identifier: NCT02998957. Recruitment status: Recruiting. First posted: 21 December 2016. Last update posted: 2 October 2018. Trial registration dataset is available in Additional file 1. Protocol version 03. Issue date: 20 March 2018. Author: Carles Fernández.
KW - AECOPD
KW - AcuTENS
KW - Acupuncture
KW - COPD
KW - Dyspnoea
KW - Protocol
KW - Randomized control trial
UR - https://www.scopus.com/pages/publications/85076336943
UR - http://hdl.handle.net/20.500.14342/747
U2 - 10.1186/s13063-019-3757-x
DO - 10.1186/s13063-019-3757-x
M3 - Article
C2 - 31829276
AN - SCOPUS:85076336943
SN - 1745-6215
VL - 20
JO - Trials
JF - Trials
IS - 1
M1 - 707
ER -